
Editas Medicine (EDIT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.28 per share a year ago.
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $47.01M |
| Gross Profit (TTM) | $-37.95M |
| EBITDA | $-81.03M |
| Operating Margin | -167.30% |
| Return on Equity | -118.80% |
| Return on Assets | -23.30% |
| Revenue/Share (TTM) | $0.46 |
| Book Value | $0.69 |
| Price-to-Book | 3.73 |
| Price-to-Sales (TTM) | 8.40 |
| EV/Revenue | 4.192 |
| EV/EBITDA | -1.36 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 232.30% |
| Shares Outstanding | $153.58M |
| Float | $115.43M |
| % Insiders | 0.18% |
| % Institutions | 80.16% |
Volatility is currently expanding

Editas Medicine (EDIT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.28 per share a year ago.

Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia New preclinical data presented at AHA Scientific Sessions demonstrating ≥90 percent LDL-C reduction maintained over 10 months supports EDIT-401's potential best-in-class profile Second IND/CTA accepted for CD70 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas Cash runway into second half of 2028, through and beyond key clinical readouts from Strive study CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the third quarter 2026 and provided business updates.

CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany.

Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.

CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company's newly appointed Chief Medical Officer, Daniel Ory, M.D.

Editas Medicine NASDAQ: EDIT is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O'Neill said during a Wells Fargo discussion.

Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare Conference Format: Fireside ChatDate: Tuesday, September 8Time: 4:30 p.m.

Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.

Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EDIT and any ticker you trade — then tracks every position and per-strategy win rate.